Shanghai Pharmaceuticals (hk) Investment Ltd - Net Worth and Insider Trading

Shanghai Pharmaceuticals (hk) Investment Ltd Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Shanghai Pharmaceuticals (hk) Investment Ltd owns 1 companies in total, including Oncternal Therapeutics Inc (ONCT) .

Click here to see the complete history of Shanghai Pharmaceuticals (hk) Investment Ltd’s form 4 insider trades.

Insider Ownership Summary of Shanghai Pharmaceuticals (hk) Investment Ltd

Ticker	Comapny	Transaction Date	Type of Owner
ONCT	Oncternal Therapeutics Inc	2020-07-21	10 percent owner

Shanghai Pharmaceuticals (hk) Investment Ltd Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Shanghai Pharmaceuticals (hk) Investment Ltd Ownership Network

Ownership Network List of Shanghai Pharmaceuticals (hk) Investment Ltd

No Data

Ownership Network Relation of Shanghai Pharmaceuticals (hk) Investment Ltd

Shanghai Pharmaceuticals (hk) Investment Ltd Owned Company Details

What does Oncternal Therapeutics Inc do?

Who are the key executives at Oncternal Therapeutics Inc?

Shanghai Pharmaceuticals (hk) Investment Ltd is the 10 percent owner of Oncternal Therapeutics Inc. Other key executives at Oncternal Therapeutics Inc include director & Executive Chairman Robert James Wills , Chief Scientific Officer Gunnar F. Kaufmann , and Chief Medical Officer Salim Yazji .

Oncternal Therapeutics Inc (ONCT) Insider Trades Summary

Over the past 18 months, Shanghai Pharmaceuticals (hk) Investment Ltd made no insider transaction in Oncternal Therapeutics Inc (ONCT). Other recent insider transactions involving Oncternal Therapeutics Inc (ONCT) include a net purchase of 9,020 shares made by Robert James Wills , a net purchase of 150,000 shares made by James B Breitmeyer , and a net purchase of 30,000 shares made by Richard G Vincent .

In summary, during the past 3 months, insiders sold 0 shares of Oncternal Therapeutics Inc (ONCT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 980 shares of Oncternal Therapeutics Inc (ONCT) were sold and 23,880 shares were bought by its insiders, resulting in a net purchase of 22,900 shares.

Oncternal Therapeutics Inc (ONCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Oncternal Therapeutics Inc Insider Transactions

No Available Data

Shanghai Pharmaceuticals (hk) Investment Ltd Mailing Address

Above is the net worth, insider trading, and ownership report for Shanghai Pharmaceuticals (hk) Investment Ltd. You might contact Shanghai Pharmaceuticals (hk) Investment Ltd via mailing address: C/o Oncternal Therapeutics, Inc., 12230 El Camino Real, Suite 300, San Diego Ca 92130.

Discussions on Shanghai Pharmaceuticals (hk) Investment Ltd

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.